


echnology Assessment of Next Generation Sequencing in Personalized (

Whole Genome Sequencing in Personalized Oncology

V Retèl(1), W van Harten(1), M Joore(2), M IJzerman(3), H Koffijberg(3), V Coupé(4), G Frederix(5), T Feenstra(6), C Uyl(7), I Eekhout(1), M van de Vijver(8), J Aerts(9), A van den Eertwegh(4), E Smit(1), S Sleijfer(9), E Voest(1), M Ploem(8), S Gevers(8), A Bredenoord(5), R Butter(8), C Pasmans(5), M Van de Ven(3), D Hurkmans(9), N Giesbertz(5), C Mitchell(8), E Cuppen(5)


(1)Netherlands Cancer Institute; (2)Maastricht University Medical Center; (3)University Medical Center




Large variability between Next Generation Sequencing (NGS) tests throughout laboratories in the Netherlands.




- To expand molecular profiling of tumors in order to improve immuneand targeted treatment selection and outcomes in patients with
- Increasing application of immunotherapy, while only a selected group will benefit: need for biomarker
- Consequence: \sqrt{q} quality of life due to side effects and \wedge healthcare costs.
- How can we apply NGS to select patients who will benefit from immuno- or targeted therapy?



- advanced melanoma and NSCLC . WP: 1,2,3
- To project long-term cost-effectiveness, budget impact, and relevant patient, organizational & legal issues related to the introduction of WGS compared to standard diagnostics. WP: 4,5,6






PALGA


RATIONALE

DATAFLOW



 Σ

1	Cross sectional WGS, clin and epi patient level data
2	Genetic yield for WGS, TGP and single test strategies
3	Patient level WGS data for WP2 patients (ID)
4	Identifier for patients included in WP2 study (ID)
5	Questionair_Utility and clinical unit cost data
6	Health benefits and harms - various scenarios
7	Unit cost for WGS, TGP and single test strategies
8	Cost data
9	Scenario data
10	Clinical and survival data, data over- and under treatment
11	Data/scenarios concerning patient perspectives
Α	Clin relevant patient level WGS data (protocol module)
В	Clin relevant patient level pathol data (protocol module)
С	Longitudinal patient level study data covering diagnosis-death (ID)
D	longitudinal epi, clin and pathol patient level data, also WP2 patient (ID)
Х	Patient registry epi, clin and pathol data



0 5 10 15 20 25 30 35 Time

outcomes

outcomes

0 5 10 15 20 25 30 35 Time

Survival

Quality of life



- Project aimed at improving personalized oncology
- Storage of large amounts of biological data in a biobank
- FAIR handling of biological data

Zilveren Kruis

achmea 🚺


ZonMw

KWF

KANKER

BESTRIJDIN

Nationwide organization of reporting molecular data \bullet



GROUP

0 5 10 15 20 25 30 35